Immunological and pathogenic properties ofpoliovirus variants selected for resistance to antiviral drug V-073

Antiviral Therapy

Volumn 16, Issue 7, 2011, Pages 999-1004

  Kouiavskaia, Diana V ^a   Dragunsky, Eugenia M ^a   Liu, Hong Mei ^b   Oberste, M Steven ^b   Collett, Marc S ^c   Chumakov, Konstantin M ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ViroDefense Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD1 ANTIGEN; HUMAN IMMUNOGLOBULIN; UNCLASSIFIED DRUG; V 073; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CAPSID PROTEINS; CELL LINE; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEUTRALIZATION TESTS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL;

EID: 80055064699     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1838     Document Type: Article

References (11)

1. Committee on Development of a Polio Antiviral and its Potential Role in Global Poliomyelitis Eradication, National Research Council. Exploring the role of antiviral drugs in the eradication of polio: workshop report. Washington: The National Academies Press 2006. (Accessed 14 June 2011.) Available from http://www.nap.edu/catalog/php?record-id=11599
2. Oberste MS, Moore D, Anderson B, et al. In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother 2009; 53:4501-4503.
3. Buontempo PJ, Cox S, Wright-Minogue J, et al. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother 1997; 41:1220-1225. (Pubitemid 27231417)
4. World Health Organization. Manual for the virological investigation of polio. WHO/EPI/GEN/97.01. Geneva: World Health Organization 1997. (Accessed 14 June 2011.) Available from http://whqlibdoc.who.int/hq/1997/WHO-EPI-GEN-97.01. pdf
5. Maintenance and distribution of transgenic mice susceptible to human viruses. Bull World Health Organ 1993; 71:497-502.
6. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, National Research Council. Guide for the care and use of laboratory animals. 8th ed. Washington: National Academies Press 2010. (Accessed 14 June 2011.) Available from http://www.nap.edu/catalog.php?record-id=12910
7. Ivanov A, Dragunsky E, Ivanova O, et al. Determination of poliovirus-specific IgA in saliva by ELISA tests. J Virol Methods 2005; 126:45-52. (Pubitemid 40558742)
8. Rezapkin G, Neverov A, Cherkasova E, et al. Repertoire of antibodies against type 1 poliovirus in human sera. J Virol Methods 2010; 169:322-331.
9. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 1990; 63:353-362.
10. Koike S, Taya C, Kurata T, et al. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A 1991; 88:951-955. (Pubitemid 21916142)
11. Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neural pathways. J Infect Dis 1992; 166:747-752.